NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

August 31, 2023

Conditions

Breast Cancer

Interventions

DRUG

HS-10352

Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.

Trial Locations (3)

200000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Unknown

RECRUITING

SUN YAT-SEN Memorial Hospital, Guanzhou

RECRUITING

Hunan Cancer Hospital, Changsha